Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone.

Swerdlow, Anthony J; Cooke, Rosie; Albertsson-Wikland, Kerstin; Borgström, Birgit; Butler, Gary; Cianfarani, Stefano; Clayton, Peter; Coste, Joël; Deodati, Annalisa; Ecosse, Emmanuel; Gausche, Ruth; Giacomozzi, Claudio; Kiess, Wieland; Hokken-Koelega, Anita C S; Kuehni, Claudia E; Landier, Fabienne; Maes, Marc; Mullis, Primus-E; Pfaffle, Roland; Sävendahl, Lars; ... (2015). Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone. Hormone research in paediatrics, 84(3), pp. 172-183. Karger 10.1159/000435856

Preview

Text Swerdlow HormResPaediatr 2015.pdf - Published Version Available under License Publisher holds Copyright. Download (194kB) | Preview

BACKGROUND

The long-term safety of growth hormone treatment is uncertain. Raised risks of death and certain cancers have been reported inconsistently, based on limited data or short-term follow-up by pharmaceutical companies.

PATIENTS AND METHODS

The SAGhE (Safety and Appropriateness of Growth Hormone Treatments in Europe) study assembled cohorts of patients treated in childhood with recombinant human growth hormone (r-hGH) in 8 European countries since the first use of this treatment in 1984 and followed them for cause-specific mortality and cancer incidence. Expected rates were obtained from national and local general population data. The cohort consisted of 24,232 patients, most commonly treated for isolated growth failure (53%), Turner syndrome (13%) and growth hormone deficiency linked to neoplasia (12%). This paper describes in detail the study design, methods and data collection and discusses the strengths, biases and weaknesses consequent on this.

CONCLUSION

The SAGhE cohort is the largest and longest follow-up cohort study of growth hormone-treated patients with follow-up and analysis independent of industry. It forms a major resource for investigating cancer and mortality risks in r-hGH patients. The interpretation of SAGhE results, however, will need to take account of the methods of cohort assembly and follow-up in each country.

Interest & Impact

Downloads

210 since deposited on 11 Feb 2016
14 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item